What is Novan, Inc. (NOVN) stock price today?

Novan, Inc. (NOVN) is currently trading at $0.09, down 24.84% today.

What is NOVN P/E ratio?

Novan, Inc.'s P/E ratio is -0.11. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is NOVN return on equity (ROE)?

Novan, Inc.'s return on equity (ROE) is -170.66%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Novan, Inc.'s market cap?

Novan, Inc. has a market capitalization of $2.64M.

NASDAQ · Biotechnology

Novan, Inc. (NOVN) Stock

$0.09 -24.84% NASDAQ: NOVN Healthcare

Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions.

Valuation

Metric	Value
Price	$0.09
Market Cap	$2.64M
P/E Ratio	-0.11
P/B Ratio	0.45
P/S Ratio	0.11
EPS (TTM)	$-0.89
52-Week High	$3.33
52-Week Low	$0.08
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-170.66%
ROA	-21.66%
ROCE	-80.56%
Gross Margin	68.74%
Operating Margin	-149.90%
Net Margin	-82.85%
Debt/Equity	0.85
Current Ratio	0.91

Annual Financials (USD)

Metric	2018	2019	2020	2021	2022
Revenue	$6.0M	$4.0M	$4.0M	$3.0M	$24.0M
Operating Profit	$-29.0M	$-31.0M	$-30.0M	$-30.0M	$-35.0M
Net Profit	$-13.0M	$-31.0M	$-30.0M	$-29.0M	$-20.0M
EPS	$-4.91	$-11.72	$-3.05	$-1.69	$-0.89
Op Margin	-476.7%	-685.5%	-718.0%	-1060.1%	-149.9%

Balance Sheet (USD)

Metric	2018	2019	2020	2021	2022
Total Assets	$26.0M	$29.0M	$47.0M	$69.0M	$90.0M
Total Liabilities	$21.0M	$53.0M	$44.0M	$51.0M	$86.0M
Cash	$8.0M	$14.0M	$36.0M	$47.0M	$12.0M
Borrowings	$8.0M	$6.0M	$1.0M	$4.0M	$4.0M

Latest News

South Korean stocks collapse amid Asian tech rout AFP · Jul 29, 2026 As AI Anxiety Spreads, Hyperscaler Default Bets Are Spiking Barrons.com · Jul 29, 2026 EduBlock Pro: An STPI and DPIIT Recognized Platform Strengthening Public Examination Integrity PR Newswire · Jul 29, 2026 FFIV Q2 Deep Dive: AI Demand and Hybrid Cloud Tailwinds Drive Results, Margin Outlook Cautious StockStory · Jul 29, 2026 Why luxury hotels are thriving amid the global cost-of-living crisis Hotel Management Network · Jul 29, 2026

Cash Flow (USD)

Metric	2018	2019	2020	2021	2022
Operating Cash Flow	$-29.0M	$-20.0M	$-31.0M	$-25.0M	$-31.0M
Investing Cash Flow	$-2.0M	$-1.0M	$-1.0M	$-17.0M	$-23.0M
Financing Cash Flow	$35.0M	$26.0M	$87.0M	$50.0M	$16.0M
Net Cash Flow	$6.0M	$6.0M	$22.0M	$12.0M	$-34.0M
Free Cash Flow	$-30.0M	$-20.0M	$-32.0M	$-34.0M	$-35.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.20
FCF Yield	-1333.56%
Quick Ratio	0.89
Interest Coverage	-24.37
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AFMDAffimed N.V.	$0.18	+0.00%	-0.02	$2.98M	0.00%
ARAVAravive, Inc.	$0.04	-13.39%	-0.02	$2.95M	0.00%
BPTSBiophytis S.A.	$8.22	-13.47%	-0.57	$2.61M	0.00%
EIGRQEiger BioPharmaceuticals, Inc.	$8.50	+6.25%	-0.17	$12.59M	0.00%
MTPMidatech Pharma plc	$0.29	-18.50%	-0.02	$1.98M	0.00%

About Novan, Inc.

Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.

Novan, Inc. is headquartered in US.

Novan, Inc. (NOVN) stock trades at $0.09 with a market capitalization of $2.64M. The stock is valued at a price-to-earnings (P/E) ratio of -0.11, price-to-book of 0.45, price-to-sales of 0.11. Over the past 52 weeks the stock has ranged between $0.08 and $3.33, and currently trades 97.3% below its 52-week high.

On profitability, Novan, Inc. generates a return on equity (ROE) of -170.66%, return on capital employed of -80.56%, an operating margin of -149.90%, a net profit margin of -82.85%.

Official website: www.novan.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1166.51 -1.36% JNJ Johnson & Johnson $248.61 -5.73% ABBV AbbVie Inc. $274.31 -2.42% MRK Merck & Company, Inc. Common Stock (new) $141.98 -2.39% UNH UnitedHealth Group Incorporated Common Stock (DE) $377.76 -0.20% NVS Novartis AG $142.41 -0.99% TMO Thermo Fisher Scientific Inc $663.04 +0.12% AZN AstraZeneca PLC $155.82 -1.59% AMGN Amgen Inc. $412.84 -1.13% GILD Gilead Sciences, Inc. $147.92 -1.67% ABT Abbott Laboratories $102.67 +0.83% NVO Novo Nordisk A/S $38.06 -1.35%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides